T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Becton Dickinson
BDX
|
+$3.46B |
| 2 |
UnitedHealth
UNH
|
+$2.79B |
| 3 |
Salesforce
CRM
|
+$2.38B |
| 4 |
Sherwin-Williams
SHW
|
+$1.41B |
| 5 |
Philip Morris
PM
|
+$1.34B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$4.44B |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$2.97B |
| 3 |
GE Aerospace
GE
|
+$2.3B |
| 4 |
HCA Healthcare
HCA
|
+$2.17B |
| 5 |
American International
AIG
|
+$1.68B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.68% |
| 2 | Healthcare | 19.49% |
| 3 | Consumer Discretionary | 13.07% |
| 4 | Financials | 11.17% |
| 5 | Communication Services | 8.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
QVCGA
2176
DELISTED
QVC Group Inc Series A
QVCGA
| $552K | ﹤0.01% |
3,849
+620
| +19% | +$120K |
|
2177
National Beverage
FIZZ
$2.93B
| $551K | ﹤0.01% |
11,252
+2,008
| +22% | +$93.7K |
|
|
PGRE
2178
DELISTED
Paramount Group
PGRE
| $551K | ﹤0.01% |
76,170
+1,304
| +2% | +$11.8K |
|
|
AZEK
2179
DELISTED
The AZEK Co
AZEK
| $548K | ﹤0.01% |
32,738
+6,267
| +24% | +$129K |
|
2180
ImmunityBio
IBRX
$8.11B
| $546K | ﹤0.01% |
146,717
-18,404
| -11% | -$73.9K |
|
|
PRO
2181
DELISTED
PROS Holdings
PRO
| $546K | ﹤0.01% |
20,811
+344
| +2% | +$9.72K |
|
2182
PetMed Express
PETS
$43.4M
| $545K | ﹤0.01% |
27,380
-2,293
| -8% | -$51.2K |
|
2183
Simulations Plus
SLP
$370M
| $542K | ﹤0.01% |
10,983
-1,969
| -15% | -$92.9K |
|
|
NWLI
2184
DELISTED
National Western Life Group, Inc. Class A
NWLI
| $539K | ﹤0.01% |
2,657
-18
| -0.7% | -$3.68K |
|
|
SPWR
2185
DELISTED
SunPower Corporation Common Stock
SPWR
| $538K | ﹤0.01% |
34,025
-446
| -1% | -$8.04K |
|
2186
Century Communities
CCS
$2.04B
| $536K | ﹤0.01% |
11,925
+148
| +1% | +$7.48K |
|
2187
Healthcare Services Group
HCSG
$1.45B
| $536K | ﹤0.01% |
30,798
+384
| +1% | +$6.62K |
|
2188
Installed Building Products
IBP
$6.54B
| $533K | ﹤0.01% |
6,414
+221
| +4% | +$18.9K |
|
|
MDRX
2189
DELISTED
Veradigm Inc. Common Stock
MDRX
| $533K | ﹤0.01% |
35,970
+15
| +0% | +$280 |
|
|
EQRXW
2190
DELISTED
EQRx, Inc. Warrant
EQRXW
| $532K | ﹤0.01% |
656,593
| – | – |
|
2191
Aclaris Therapeutics
ACRS
$863M
| $531K | ﹤0.01% |
38,029
+6,460
| +20% | +$90.5K |
|
|
RVNC
2192
DELISTED
Revance Therapeutics, Inc.
RVNC
| $530K | ﹤0.01% |
38,332
+428
| +1% | +$6.59K |
|
|
KAMN
2193
DELISTED
Kaman Corp
KAMN
| $529K | ﹤0.01% |
16,916
+244
| +1% | +$9.05K |
|
2194
Standard Motor Products
SMP
$870M
| $527K | ﹤0.01% |
11,723
-351
| -3% | -$14.6K |
|
2195
Coeur Mining
CDE
$19B
| $525K | ﹤0.01% |
172,592
+18,637
| +12% | +$73.2K |
|
|
SNBR
2196
DELISTED
Sleep Number
SNBR
| $524K | ﹤0.01% |
16,922
+127
| +0.8% | +$5.39K |
|
2197
NextNav
NN
$3.29B
| $522K | ﹤0.01% |
+230,068
| New | +$1.11M |
|
2198
Skywest
SKYW
$4.21B
| $521K | ﹤0.01% |
24,510
+362
| +1% | +$9.51K |
|
|
ROVR
2199
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $521K | ﹤0.01% |
138,513
-195,176
| -58% | -$1.01M |
|
2200
Weatherford International
WFRD
$6.6B
| $520K | ﹤0.01% |
24,544
+9,944
| +68% | +$317K |
|
Similar funds
T. Rowe Price Associates's Q2 2022 Portfolio in Review
As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
- T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
- T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
- T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
- T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
- T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.
Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.